Imugene MD & CEO Leslie Chong said: “We've now seen a very significant number of patients dosed with VAXINIA as part of the MAST study, with those patients suffering as a result of a variety of tumour types. It's exciting that we're getting so close to finding out the impact that this treatment is having for these patients in need.”
Assuming that each cohort is fully recruited and dosed, ie.12 patients for the monotherapy dose escalation and 12 patients for the combination dose escalation, then the number of patients dosed with VAXINIA to date would be approximately 72 in the MAST trial of between 52 to 100. Over the next few months Imugene will announce the RP2D (recommended phase 2 dose) expansion to be administered to 10 very lucky patients. The trial is at the pointy end, especially with the data results open for the science to be seen via many hNIS scans taken every few weeks.
Regards.
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)